Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.
The unique targeting capabilities and promising clinical trial results of antibody- drug conjugates (ADCs) have made them an exciting and promising treatment in the fight against cancer. According to recent analysis, experts anticipate the ADC market to be worth $10 billion annually by 2025. However, despite this tremendous growth, drugmakers still face a number of challenges in the manufacturing process for ADCs. Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.
DOWNLOAD TO LEARN MORE>>>>